Hepatitis C: global epidemiology and strategies for control

Clinical Microbiology and Infection

Volumn 22, Issue 10, 2016, Pages 833-838

  Lanini, S ^a   Easterbrook, P J ^b   Zumla, A ^c,d   Ippolito, G ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Control; Epidemiology; Eradication; Global health; Hepatitis C

Indexed keywords

DISEASE CONTROL; HEPATITIS C; HUMAN; PANDEMIC; PRIORITY JOURNAL; REVIEW; WORLD HEALTH ORGANIZATION; DEVELOPED COUNTRY; DEVELOPING COUNTRY; ECONOMICS; HEALTH; HEPATITIS C, CHRONIC; ORGANIZATION AND MANAGEMENT; PREVALENCE; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

ANTIVIRUS AGENT;

ANTIVIRAL AGENTS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; GLOBAL HEALTH; HEPATITIS C, CHRONIC; HUMANS; PREVALENCE; SOCIOECONOMIC FACTORS; WORLD HEALTH ORGANIZATION;

EID: 84994756865     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.07.035     Document Type: Review

References (85)

1. [1] Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M., Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:4902 (1989), 359–362.
2. [2] WHO Hepatitis C Fact sheet, updated July 2016. http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed 24 August 2016).
3. [3] Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:9859 (2012), 2095–2128.
4. [4] Global Burden of Disease Study 2013 Collaborators, Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386:9995 (2015), 743–800.
5. [5] Westbrook, R.H., Dusheiko, G., Natural history of hepatitis C. J Hepatol 61:1 Suppl. (2014), S58–S68.
6. [6] Cunningham, E.B., Applegate, T.L., Lloyd, A.R., Dore, G.J., Grebely, J., Mixed HCV infection and reinfection in people who inject drugs–impact on therapy. Nat Rev Gastroenterol Hepatol 12:4 (2015), 218–230.
7. [7] Layden, J.E., Phillips, R.O., Owusu-Ofori, S., Sarfo, F.S., Kliethermes, S., Mora, N., et al. High frequency of active HCV infection among seropositive cases in west Africa and evidence for multiple transmission pathways. Clin Infect Dis 60:7 (2015), 1033–1041.
8. [8] Smith, D.B., Bukh, J., Kuiken, C., Muerhoff, A.S., Rice, C.M., Stapleton, J.T., et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59:1 (2014), 318–327.
9. [9] European Association for Study of Liver, EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 63:1 (2015), 199–236.
10. [10] IDSA AASLD Recommendations for Testing, Managing, and Treating Hepatitis C, March 10, 2016. http://www.hcvguidelines.org.
11. [11] Updated version WHO Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection, April 2016, World Health Organization, Geneva http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/.
12. [12] Ippolito, G., Capobianchi, M.R., Lanini, S., Antonelli, G., Is hepatitis C virus eradication around the corner only 25 years after its discovery?. Int J Antimicrob Agents 45:2 (2015), 111–112.
13. [13] Mohd Hanafiah, K., Groeger, J., Flaxman, A.D., Wiersma, S.T., Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:4 (2013), 1333–1342.
14. [14] Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:1 Suppl. (2014), S45–S57.
15. [15] Shire, N.J., Sherman, K.E., Epidemiology of Hepatitis C Virus: a Battle on New Frontiers. Gastroenterol Clin North Am 44:4 (2015), 699–716.
16. [16] Abd Elrazek, A.E., Bilasy, S.E., Elbanna, A.E., Elsherif, A.E., Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis. Medicine (Baltimore), 93(28), 2014, e204.
17. [17] Ministry of Health and Population [Egypt], El-Zanaty and Associates [Egypt], and ICF International, Egypt Health Issues Survey 2015. 2015, Ministry of Health and Population and ICF International, Cairo, Egypt and Rockville, Maryland, USA.
18. [18] Njouom, R., Caron, M., Besson, G., Ndong-Atome, G.R., Makuwa, M., Pouillot, R., et al. Phylogeography, risk factors and genetic history of hepatitis C virus in Gabon, central Africa. PLoS One, 7(8), 2012, e42002.
19. [19] Riou, J., Aït Ahmed, M., Blake, A., Vozlinsky, S., Brichler, S., Eholié, S., et al., HCV epidemiology in Africa group. Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta-analysis. J Viral Hepat 23:4 (2016), 244–255.
20. [20] Tserenpuntsag, B., Nelson, K., Lamjav, O., Triner, W., Smith, P., Kacica, M., et al. Prevalence of and risk factors for hepatitis B and C infection among Mongolian blood donors. Transfusion 50:1 (2010), 92–99.
21. [21] Saraswat, V., Norris, S., de Knegt, R.J., Sanchez Avila, J.F., Sonderup, M., Zuckerman, E., et al. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. J Viral Hepat 22:Suppl. 1 (2015), 6–25.
22. [22] Umer, M., Iqbal, M., Hepatitis C virus prevalence and genotype distribution in Pakistan: comprehensive review of recent data. World J Gastroenterol 22:4 (2016), 1684–1700.
23. [23] Sharvadze, L., Nelson, K.E., Imnadze, P., Karchava, M., Tsertsvadze, T., Prevalence of HCV and genotypes distribution in general population of Georgia. Georgian Med News 165 (2008), 71–77.
24. [24] El-Ghitany, E.M., Abdel Wahab, M.M., Abd El-Wahab, E.W., Hassouna, S., Farghaly, A.G., A comprehensive hepatitis C virus risk factors meta-analysis (1989–2013): do they differ in Egypt?. Liver Int 35:2 (2015), 489–501.
25. [25] Malhotra, P., Malhotra, V., Malhotra, N., Singh, I., Chugh, A., Chaturvedi, A., Epidemiological Profile of Hepatitis C Patients at India's New Hub – Haryana. Adv Res Gastroenterol Hepatol, 1(1), 2015 ARGH.MS.ID.555554.
26. [26] Eze, J.C., Ibeziako, N.S., Ikefuna, A.N., Nwokoye, I.C., Uleanya, N.D., Ilechukwu, G.C., Prevalence and risk factors for hepatitis C and human immunodeficiency virus coinfection among children in Enugu, Nigeria. Afr J Infect Dis 8:1 (2014), 5–8.
27. [27] Rerambiah, L.K., Rerambiah, L.E., Bengone, C., Djoba Siawaya, J.F., The risk of transfusion-transmitted viral infections at the Gabonese National Blood Transfusion Centre. Blood Transfus 12:3 (2014), 330–333.
28. [28] Kane, A., Lloyd, J., Zaffran, M., Simonsen, L., Kane, M., Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 77:10 (1999), 801–807.
29. [29] Pépin, J., Abou Chakra, C.N., Pépin, E., Nault, V., Valiquette, L., Evolution of the global burden of viral infections from unsafe medical injections, 2000–2010. PLoS One, 9(6), 2014, e99677.
30. [30] Global database on blood safety. Blood transfusion safety [webpage], 2011, World Health Organization, Geneva http://www.who.int/bloodsafety/global_database/en/ (accessed 10 March 2016).
31. [31] CDC Healthcare-Associated Hepatitis B and C Outbreaks Reported to the Centers for Disease Control and Prevention (CDC) 2008–2014. http://www.cdc.gov/hepatitis/outbreaks/healthcarehepoutbreaktable.htm.
32. [32] de Lédinghen, V., Trimoulet, P., Mannant, P.R., Dumas, F., Champbenoît, P., Baldit, C., et al. Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years). J Hepatol 46:1 (2007), 19–25.
33. [33] Lanini, S., Abbate, I., Puro, V., Soscia, F., Albertoni, F., Battisti, W., et al. Molecular epidemiology of a hepatitis C virus epidemic in a haemodialysis unit: outbreak investigation and infection outcome. BMC Infect Dis, 10, 2010, 257.
34. [34] Ross, R.S., Viazov, S., Khudyakov, Y.E., Xia, G.L., Lin, Y., Holzmann, H., et al. Transmission of hepatitis C virus in an orthopedic hospital ward. J Med Virol 81:2 (2009), 249–257.
35. [35] Martínez-Bauer, E., Forns, X., Armelles, M., Planas, R., Solà, R., Vergara, M., et al. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol 48 (2008), 20–27.
36. [36] Suryaprasad, A.G., White, J.Z., Xu, F., Eichler, B.A., Hamilton, J., Patel, A., et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis 59:10 (2014), 1411–1419.
37. [37] Negro, F., Epidemiology of hepatitis C in Europe. Dig Liver Dis 46:Suppl. 5 (2014), S158–S164.
38. [38] Judd, A., Hickman, M., Jones, S., McDonald, T., Parry, J.V., Stimson, G.V., et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 330:7481 (2005), 24–25.
39. [39] Vescio, M.F., Longo, B., Babudieri, S., Starnini, G., Carbonara, S., Rezza, G., et al. Correlates of hepatitis C virus sero-positivity in prison inmates: a meta-analysis. J Epidemiol Community Health 62 (2008), 305–313.
40. [40] Allwright, S., Bradley, F., Long, J., Barry, J., Thornton, L., Parry, J.V., Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ 321 (2000), 78–82.
41. [41] Martin, N.K., Thornton, A., Hickman, M., Sabin, C., Nelson, M., Cooke, G.S., et al. Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. Clin Infect Dis, 2016 Feb 16 pii: ciw075. [Epub ahead of print].
42. [42] Hullegie, S.J., van den Berk, G.E., Leyten, E.M., Arends, J.E., Lauw, F.N., van der Meer, J.T., et al. Acute hepatitis C in the Netherlands: characteristics of the epidemic in 2014. Clin Microbiol Infect, 22(2), 2016 209.e1–3.
43. [43] Vanhommerig, J.W., Lambers, F.A., Schinkel, J., Geskus, R.B., Arends, J.E., van de Laar, T.J., et al. Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control Study. Open Forum Infect Dis, 2(3), 2015 ofv115.
44. [44] McFaul, K., Maghlaoui, A., Nzuruba, M., Farnworth, S., Foxton, M., Anderson, M., et al. Acute hepatitis C infection in HIV-negative men who have sex with men. J Viral Hepat 22:6 (2015), 535–538.
45. [45] Terrault, N.A., Dodge, J.L., Murphy, E.L., Tavis, J.E., Kiss, A., Levin, T.R., et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology 57:3 (2013), 881–889.
46. [46] El-Shabrawi, M.H., Kamal, N.M., Burden of pediatric hepatitis C. World J Gastroenterol 19:44 (2013), 7880–7888.
47. [47] Tovo, P.A., Calitri, C., Scolfaro, C., Gabiano, C., Garazzino, S., Vertically acquired hepatitis C virus infection: correlates of transmission and disease progression. World J Gastroenterol 22:4 (2016), 1382–1392.
48. [48] Benova, L., Awad, S.F., Miller, F.D., Abu-Raddad, L.J., Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt. Hepatology 61:3 (2015), 834–842.
49. [49] Benova, L., Mohamoud, Y.A., Calvert, C., Abu-Raddad, L.J., Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 59:6 (2014), 765–773.
50. [50] Cottrell, E.B., Chou, R., Wasson, N., Rahman, B., Guise, J.M., Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 158:2 (2013), 109–113.
51. [51] Luma, H.N., Eloumou, S.A., Malongue, A., Temfack, E., Noah, D.N., Donfack-Sontsa, O., et al. Characteristics of anti-hepatitis C virus antibody-positive patients in a hospital setting in Douala, Cameroon. Int J Infect Dis 45 (2016), 53–58.
52. [52] WHO Injection safety policy and global campaign. http://www.who.int/injection_safety/global-campaign/en/ (accessed 24 August 2016).
53. [53] Palmateer, N.E., Taylor, A., Goldberg, D.J., Munro, A., Aitken, C., Shepherd, S.J., et al. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One, 9(8), 2014, e104515.
54. [54] UK Home Office Advisory Council on the Misuse of Drugs. The Primary Prevention Of Hepatitis C Among Injecting Drug Users 2009. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119144/acmdhepcreport2.pdf (accessed 24 August 2016).
55. [55] Wyles, D.L., Ruane, P.J., Sulkowski, M.S., Dieterich, D., Luetkemeyer, A., Morgan, T.R., et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 373:8 (2015), 714–725.
56. [56] Gane, E.J., Hyland, R.H., An, D., Svarovskaia, E., Pang, P.S., Brainard, D., et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology, 149(6), 2015 1454–1461.e1.
57. [57] Feld, J.J., Jacobson, I.M., Hézode, C., Asselah, T., Ruane, P.J., Gruener, N., et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 373:27 (2015), 2599–2607.
58. [58] Foster, G.R., Afdhal, N., Roberts, S.K., Bräu, N., Gane, E.J., Pianko, S., et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med 373:27 (2015), 2608–2617.
59. [59] Curry, M.P., O'Leary, J.G., Bzowej, N., Muir, A.J., Korenblat, K.M., Fenkel, J.M., et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med 373:27 (2015), 2618–2628.
60. [60] Yang, S.S., Kao, J.H., Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. Hepatol Int 10:2 (2016), 258–266.
61. [61] Castro-Sánchez, A., Shkedy, Z., Hens, N., Aerts, M., Geskus, R., Prins, M., et al. Estimating the force of infection for HCV in injecting drug users using interval-censored data. Epidemiol Infect 140:6 (2012), 1064–1074.
62. [62] Ward, J.W., Mermin, J.H., Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs. N Engl J Med 373:27 (2015), 2678–2680.
63. [63] Lanini, S., Nanni Costa, A., Grossi, P.A., Procaccio, F., Ricci, A., Capobianchi, M.R., et al. Liver transplant recipients and prioritization of anti-HCV therapy: an Italian cohort analysis. Liver Int 36:3 (2016), 410–417.
64. [64] Innes, H., Goldberg, D., Dillon, J., Hutchinson, S.J., Strategies for the treatment of hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?. Gut 64:11 (2015), 1800–1809.
65. [65] Bruno, S., Di Marco, V., Iavarone, M., Roffi, L., Crosignani, A., Calvaruso, V., et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol 64:6 (2016), 1217–1223.
66. [66] Edlin, B.R., Winkelstein, E.R., Can hepatitis C be eradicated in the United States?. Antiviral Res 110 (2014), 79–93.
67. [67] Aylward, B., Hennessey, K.A., Zagaria, N., Olivé, J.M., Cochi, S., When is a disease eradicable? 100 years of lessons learned. Am J Public Health 90:10 (2000), 1515–1520.
68. [68] Dowdle, W.R., The principles of disease elimination and eradication. Bull World Health Organ 76:Suppl. 2 (1998), 23–25.
69. [69] Heymann, D.L., Control, elimination, eradication and re-emergence of infectious diseases: getting the message right. Bull World Health Organ, 84(2), 2006, 82.
70. [70] Peltekian, K.M., With all the new treatment regimens, complete elimination of hepatitis C virus in Canada is a possibility! But when will Canadians have access these drugs?. Can J Gastroenterol Hepatol 28:8 (2014), 417–418.
71. [71] Thompson, A.J., Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust 204:7 (2016), 268–272.
72. [72] Public Health Agency of Canada, Hepatitis C in Canada: 2005–2010 Surveillance Report., 2011, Centre for Communicable Diseases and Infection Control, Infectious Disease Prevention and Control Branch, Public Health Agency of Canada.
73. [73] Myers, R.P., Krajden, M., Bilodeau, M., Kaita, K., Marotta, P., Peltekian, K., et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol 28 (2014), 243–250.
74. [74] Rein, D.B., Wittenborn, J.S., Weinbaum, C.M., Sabin, M., Smith, B.D., Lesesne, S.B., Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 43:1 (2011), 66–72.
75. [75] Obach, D., Yazdanpanah, Y., Esmat, G., Avihingsanon, A., Dewedar, S., Durier, N., et al. How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries. Hepatology 62:1 (2015), 31–39.
76. [76] WHO Global health sector strategy on viral hepatitis 2016–2021. http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/ (accessed 24 August 2016).
77. [77] The Global State of Harm Reduction 2012: Towards an integrated response. http://www.ihra.net/files/2012/07/24/GlobalState2012_Web.pdf (accessed 24 August 2016).
78. [78] Dore, G.J., Ward, J., Thursz, M., Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). J Viral Hepat 21:Suppl. 1 (2014), 1–4.
79. [79] Aghemo, A., Dore, G.J., Hatzakis, A., Wedemeyer, H., Razavi, H., Estimating HCV disease burden - volume 3 (editorial). J Viral Hepat 22:Suppl. 4 (2015), 1–3.
80. [80] Viral Hepatitis Resolution – Sixty-Third World Health Assembly, 2010, World Health Organization http://www.who.int/mediacentre/news/releases/2010/wha_closes_20100521/en/ (accessed 27 August 2016).
81. [81] Health Assembly approves resolution on hepatitis and mechanism to coordinate noncommunicable disease response, 2014, World Health Organization http://www.who.int/mediacentre/news/releases/2014/WHA-20140522/en/ (accessed 27 August 2016).
82. [82] United Nations General Assembly resolution A/RES/70/1 – Transforming our world: the 2030 Agenda for Sustainable Development. http://www.un.org/ga/search/view_doc.asp?symbol=A/RES/70/1&Lang=E (accessed 30 October 2015).
83. [83] Sixty-Seventh World Health Assembly 24 May 2014. http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf.
84. [84] Chhatwal, J., Kanwal, F., Roberts, M.S., Dunn, M.A., Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 162:6 (2015), 397–406.
85. [85] WHO updates patent information on treatments for Hepatitis C. http://www.who.int/phi/implementation/ip_trade/ip_patent_landscapes/en/ (accessed 24 August 2016).